Plain-English translation of NCT04913805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether can help people with a specific type of heart failure called HFpEF (heart failure with preserved ejection fraction) exercise longer and feel less tired. Researchers will also test whether adding two other supplements—propionyl-L-carnitine and nicotinamide riboside—works better than the medication alone. The study will help doctors figure out which patients benefit most from each treatment option.
People with HFpEF often struggle with exercise and shortness of breath, even though their heart's pumping strength looks normal on tests. Current treatments don't adequately address the underlying muscle and energy problems that cause these symptoms, so this trial is exploring whether this medication and supplements can improve how the body uses oxygen during exercise.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either alone, the combination of three supplements, or a placebo. You'll take your assigned pills three times daily (and one supplement twice daily if in the combination group). During visits, you'll complete exercise tests on a treadmill or bike, have heart imaging scans including an MRI to measure muscle energy use, and provide blood work to monitor your progress.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States